LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials

Article Oncology

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok et al.

Summary: The 6.5-year results of the CheckMate 067 trial demonstrate durable clinical benefits with nivolumab plus ipilimumab or nivolumab monotherapy compared to ipilimumab alone in patients with advanced melanoma.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara et al.

Summary: In patients with gastro-oesophageal adenocarcinoma, nivolumab plus chemotherapy has shown superior overall survival compared to chemotherapy alone.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Article Oncology

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Taofeek K. Owonikoko et al.

Summary: Maintenance therapy with nivolumab plus ipilimumab did not prolong overall survival (OS) for patients with extensive-disease small-cell lung cancer (ED-SCLC) who did not progress on first-line chemotherapy. However, there may be a benefit of nivolumab plus ipilimumab in patients with a tumor mutational burden of >= 13 mutations per megabase. The rates of grade 3-4 treatment-related adverse events were highest in the nivolumab plus ipilimumab group.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Pathology

Gene of the month: lymphocyte-activation gene 3 (LAG-3)

Mark P. Lythgoe et al.

Summary: LAG-3 is a coreceptor found on activated T-lymphocytes, activated B-lymphocytes, and natural killer cells, closely related to CD4 and functioning as an inhibitor of T-cell signaling. Tumor-infiltrating lymphocytes with high LAG-3 expression have been found in various cancers, and LAG-3 antagonism is being explored as a potential anticancer therapy.

JOURNAL OF CLINICAL PATHOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Immune checkpoint inhibitors in melanoma

Matteo S Carlino et al.

LANCET (2021)

添加到收藏夹

Review Medicine, General & Internal

Recent Advances in the Treatment of Melanoma

Brendan D. Curti et al.

Summary: Improvements in management have led to increased survival rates for melanoma, with advances such as sentinel-node sampling and targeted therapy reducing morbidity and enhancing treatment outcomes for advanced disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Oncology